# OnCo record paper-abiraterone-acetate-prostate-lancet-oncol-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-abiraterone-acetate-prostate-lancet-oncol-2012" ;
  schema:name "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study"@en ;
  schema:description "Phase 2 or 3 results paper on Abiraterone acetate in Prostate cancer, in The Lancet Oncology (2012), one of the most cited Europe PMC records with Abiraterone acetate in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(12)70379-0>, <https://pubmed.ncbi.nlm.nih.gov/22995653/>, <https://europepmc.org/article/MED/22995653> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(12)70379-0> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Fizazi K, Scher HI, Molina A, et al." ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .